4CMenB Vaccine
Retrospective studies in Canada, Australia, and the USA reported 30-40% declines in gonorrhea incidence after 4CMenB vaccination. The trial uses two intramuscular doses of 4CMenB given at least 28 days apart. The evidence from retrospectiv…
1 sources - 5 claims
Retrospective studies in Canada, Australia, and the USA reported 30-40% declines in gonorrhea incidence after 4CMenB vaccination. The trial uses two intramuscular doses of 4CMenB given at least 28 days apart. The evidence from retrospective 4CMenB studies has limitations because it relied on symptomatic clinic data and could not separate infection prevention from symptom attenuation. 4CMenB is an FDA-approved four-component MenB vaccine sold under the trade name Bexsero.